Reduction of microbleeds by immunosuppression in a patient with Aβ-related vascular inflammation

Andreas Traschütz1, Theophilos Tzaridis1, Arndt-Hendrik Penner1

  • 1Departments of Neurology (A.T., T.T., M.T.H.), Neuroradiology (A.-H.P., E.H.), and Neuropathology (K.K.), University of Bonn, Germany; Department of Neuroradiology (H.U.), University of Freiburg, Germany; and German Center for Neurodegenerative Disease (M.T.H.), Bonn, Germany.

Abstract

Insights

Immunosuppressive treatment may reduce and clear microhemorrhages in cerebral amyloid angiopathy (CAA)-related vascular inflammation. Long-term therapy showed fewer new and existing cortical microbleeds in a patient with CAA.

Area of Science:

  • Neurology
  • Immunology
  • Radiology

Background:

  • Cerebral amyloid angiopathy (CAA) is associated with vascular inflammation and microhemorrhages.
  • The potential for modifying microhemorrhage occurrence or clearance with treatment is not well understood.

Purpose of the Study:

  • To investigate if immunosuppressive treatment can alter microhemorrhage dynamics in CAA-related vascular inflammation.

Main Methods:

  • A single patient with histopathologically confirmed CAA-related vascular inflammation underwent over 5 years of clinical and radiologic follow-up.
  • Treatment involved a prolonged, tapered regimen of intravenous cyclophosphamide and oral steroids.

Main Results:

  • Long-term immunosuppression led to a decrease in cortical microbleeds.
  • This reduction was attributed to both the prevention of new microhemorrhages and the clearance of pre-existing ones.

Conclusions:

  • Sustained immunosuppression shows promise as a therapeutic strategy for managing cortical microbleeds in CAA.
  • Further systematic investigation of immunosuppression for inflammatory CAA phenotypes is warranted.

Related Concept Videos